By Emily Leclerc, Waisman Science Writer One of Carl Ross’s favorite stories is actually an account of one of his failures. In the early 2000s Ross, the former managing director of Waisman Biomanufacturing (WB), was …
Waisman Biomanufacturing
Waisman Biomanufacturing selects new managing director
After an extensive national search, Chris Bartley was recently selected as the new managing director of Waisman Biomanufacturing (WB). Bartley most recently served as the facility’s interim director.
A science trailblazer retires: Stem cell researcher James Thomson’s legacy changed the future of biology
James Thomson helped the scientific world turn its attention to the shape-shifting stem cells that give rise to all of the building blocks of complex living organisms, from skin and bone, to hearts and blood, to neurons and brains.
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
Clinical trial for Ebola vaccine developed at UW–Madison underway in Japan
As of this week, a phase one clinical trial to test a potential new Ebola vaccine developed by researchers at the University of Wisconsin–Madison is underway in Japan. Fifteen healthy young men* will receive two doses of the experimental vaccine. If the first group tolerates the vaccine, an additional group of up to 20 volunteers will receive a higher dose of the vaccine.
UW-Madison biomanufacturer offers essential gene-transfer capacity
Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.
Waisman Biomanufacturing to be part of UW-Madison partnership in $20 million cell-based therapy center
Waisman Biomanufacturing and Waisman affiliate investigators Randolph Ashton and Krishanu Saha will be part of a new engineering research center that will develop transformative tools and technologies for the consistent, scalable and low-cost production of …
Waisman Biomanufacturing has new managing director
Carl Ross has been selected to serve as managing director of Waisman Biomanufacturing. His appointment started July 1, following more than a year as its interim director. Located at the University of Wisconsin–Madison Waisman Center, …
An Update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy
Introduction Recognizing the emerging field of therapeutic cell-based treatments for a growing number of diseases, including the field of regenerative medicine, the National Heart, Lung, and Blood Institute (NHLBI) held a workshop in 2002, where …
Waisman Biomanufacturing plays key role in prostate cancer vaccine development
A spinoff business launched by a University of Wisconsin-Madison cancer researcher is attempting to harness the human immune system to fight prostate cancer.